Texas A&M Health Science Center’s faculty members regularly pursue innovative translational research to find solutions to some of today’s most pressing health conditions. However, some of these groundbreaking discoveries do not successfully move from the bench to the bedside because researchers find they have limited training when it comes to commercialization.
International collaboration and innovative partnerships with industry, government, speeding bench-to-bedside discoveries
Whether it’s an inhaled therapeutic that stimulates innate immunity of the lungs to prevent the spread of bacterial and viral infections, or a novel tuberculosis test that allows doctors to diagnose the infectious disease within minutes, the partnerships between academic institutions, their spinoff companies, industry, and government are the driving force behind advancing these products to the market — and on faster timelines than ever before.
Researchers at the Texas A&M Health Science Center (TAMHSC) and the University of Texas MD Anderson Cancer Center have developed a new therapy to stimulate the body’s natural immune system, thereby providing effective protection against a wide range of life-threatening infectious diseases.